The Ganoderma Lucidum Polysaccharides market is primarily divided by type, reflecting the molecular architecture of the extracted biopolymers. Beta‑glucan variants, characterized by a (1→3)(1→6)‑β‑D‑glucose backbone, dominate the segment due to their well‑documented immunomodulatory activity and higher commercial extraction yields; they account for roughly half of total production volume. Mannose‑rich polysaccharides, featuring a mannose‑dominant monosaccharide composition, represent a smaller yet strategically important niche, leveraged for targeted anti‑inflammatory formulations and contributing about 20 % of market revenue. Heteropolysaccharides, complex assemblies of glucose, mannose, galactose, and uronic acids, comprise the remaining 30 % and are prized for synergistic bio‑effects in multi‑component nutraceuticals. Each subtype influences the overall market size by dictating downstream processing costs, regulatory pathways, and end‑user pricing, thereby shaping investment decisions across the supply chain.